Three-week radiation course a safe option for breast cancer patients undergoing reconstruction, trial shows
Results of a national clinical trial led by the Alliance for Clinical Trials in Oncology in conjunction with NRG Oncology and the Canadian Cancer Trials Group show that a shorter, three-week radiation schedule following a mastectomy is as safe and effective as the standard five-week treatment for women undergoing breast reconstruction. The results of the RT CHARM trial (Alliance A221505) are…
A national clinical trial has found that a three-week radiation course after mastectomy and breast reconstruction is as safe and effective as the traditional five-week treatment. The RT CHARM trial, led by the Alliance for Clinical Trials in Oncology, NRG Oncology, and the Canadian Cancer Trials Group, involved 828 patients at 209 medical centers in the United States and Canada.
The study, published in the Journal of Clinical Oncology, shows that shorter radiation therapy following mastectomy does not increase complications or reduce the chances of a cure, allowing women to recover faster and return to their daily lives sooner.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
